BF2.649, an H3R Inverse Agonist, Promotes Vigilance in Narcolepsy Models, Targeting Excessive Daytime Sleepiness.

Narcolepsy is a disabling neurological disorder primarily characterized by Excessive Daytime Sleepiness (EDS) and cataplexy, affecting approximately 25 per 100,000 Caucasians. Most patients exhibit significantly decreased cerebrospinal fluid levels of orexins, hypothalamic peptides crucial for wake-promoting activity, suggesting a neurodegenerative or autoimmune etiology. Current pharmacological treatments for EDS, such as Modafinil, primarily act as stimulants. There remains a critical need for therapies that target the underlying mechanisms of wakefulness regulation, such as the histaminergic system, which BF2.649 aims to address.

The provided abstract snippet indicates that BF2.649, an H3R inverse agonist, was investigated for its ability to promote vigilance. The study utilized knockout mice as a preclinical animal model, implying an investigation into a specific genetic or pathway-related aspect of narcolepsy. However, the abstract does not specify the exact dose, route of administration, frequency, or duration of treatment with BF2.649. The primary endpoint was implied to be the promotion of vigilance, but no specific assay names (e.g., EEG, actigraphy) or control arm details were provided.

The abstract snippet indicates that BF2.649, acting as an H3R inverse agonist, significantly promoted vigilance.

BF2.649, an H3R inverse agonist, promotes significantly vigilance in mice knock out for [an unspecified gene/pathway related to narcolepsy]. However, the abstract does not provide specific quantitative data, such as percentages, fold-changes, or p-values, to elaborate on the extent or statistical significance of this vigilance promotion. The exact knockout mouse model used (e.g., orexin-deficient mice) is also not specified in the provided text, limiting the precise interpretation of the findings regarding the specific mechanism or magnitude of effect.